Alley, S. C., Okeley, N. M., & Senter, P. D. (2010). Antibody–drug conjugates: targeted drug delivery for cancer. Current Opinion in Chemical Biology, 14(4), 529–537. https://doi.org/10.1016/j.cbpa.2010.06.170
Baurin, N., Aboul-Ela, F., Barril, X., Davis, B., Drysdale, M., Dymock, B., Finch, H., Fromont, C., Richardson, C., Simmonite, H., & Hubbard, R. E. (2004). Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets. Journal of Chemical Information and Modeling, 44(6), 2157–2166. https://doi.org/10.1021/ci049806z
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nature Reviews Immunology, 10(5), 345–352. https://doi.org/10.1038/nri2747
Bissantz, C., Kuhn, B., & Stahl, M. (2010). A Medicinal Chemist’s Guide to Molecular Interactions. Journal of Medicinal Chemistry, 53(14), 5061–5084. https://doi.org/10.1021/jm100112j
Blake, J. F. (2005). Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate. Medicinal Chemistry, 1(6), 649–655. https://doi.org/10.2174/157340605774598081
Bradbury, A. R. M., Sidhu, S., Dübel, S., & McCafferty, J. (2011). Beyond natural antibodies: the power of in vitro display technologies. Nature Biotechnology, 29(3), 245–254. https://doi.org/10.1038/nbt.1791
Brignier, A. C., & Gewirtz, A. M. (2010). Embryonic and adult stem cell therapy. Journal of Allergy and Clinical Immunology, 125(2), S336–S344. https://doi.org/10.1016/j.jaci.2009.09.032
Castanotto, D., & Rossi, J. J. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457(7228), 426–433. https://doi.org/10.1038/nature07758
Chandra, N. (2009). Computational systems approach for drug target discovery. Expert Opinion on Drug Discovery, 4(12), 1221–1236. https://doi.org/10.1517/17460440903380422
Colquhoun, D. (1998). Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. British Journal of Pharmacology, 125(5), 923–947. https://doi.org/10.1038/sj.bjp.0702164
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008). Recent Developments in Fragment-Based Drug Discovery. Journal of Medicinal Chemistry, 51(13), 3661–3680. https://doi.org/10.1021/jm8000373
Copeland, Robert Allen. (2005). Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists: Vol. Methods of biochemical analysis. J. Wiley. https://onlinelibrary.wiley.com/doi/book/10.1002/9781118540398
Cornish-Bowden, Athel. (2004). Fundamentals of enzyme kinetics (3rd ed). Portland.
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22(2), 151–185. https://doi.org/10.1016/S0167-6296(02)00126-1
Ducry, L., & Stump, B. (2010). Antibody−drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjugate Chemistry, 21(1), 5–13. https://doi.org/10.1021/bc9002019
Dunlop, J. (2008). High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nature Reviews Drug Discovery, 7(4), 358–368. https://doi.org/10.1038/nrd2552
Engel, Thomas & Gasteiger, J. (2003). Chemoinformatics: a textbook.
Fitt, R., & Nodder, E. (2010). Setting the threshold for industrial application: the UK diverges from Europe. Journal of Intellectual Property Law & Practice, 5(8), 560–565. https://doi.org/10.1093/jiplp/jpq061
Gasteiger, J. (2003). Handbook of chemoinformatics: from data to knowledge. https://onlinelibrary.wiley.com/doi/book/10.1002/9783527618279
Gibb, Alasdair J., Foreman, John C., & Johansen, Torben. (2011). Textbook of receptor pharmacology (3rd ed). CRC Press.
Grimm, D. (2009). Small silencing RNAs: State-of-the-art. Advanced Drug Delivery Reviews, 61(9), 672–703. https://doi.org/10.1016/j.addr.2009.05.002
Gu, Jenny & Bourne, Philip E. (2008). Structural bioinformatics: Vol. Methods of biochemical analysis (2nd ed). Wiley.
Holliger, P., & Hudson, P. J. (2005). Engineered antibody fragments and the rise of single domains. Nature Biotechnology, 23(9), 1126–1136. https://doi.org/10.1038/nbt1142
Hopkins, A. L., & Groom, C. R. (2002). Opinion: The druggable genome. Nature Reviews Drug Discovery, 1(9), 727–730. https://doi.org/10.1038/nrd892
Hopkins, A. L., Groom, C. R., & Alex, A. (2004). Ligand efficiency: a useful metric for lead selection. Drug Discovery Today, 9(10), 430–431. https://doi.org/10.1016/S1359-6446(04)03069-7
Human embryonic stem cells: Derivation, culture, and differentiation: A review. (n.d.).
Ikura, M., & Inouye, M. (1998). NMR structure of the histidine kinase domain of the : E. coli: osmosensor EnvZ : Article : Nature. Nature, 396(6706), 88–92. https://doi.org/10.1038/23968
Jarnagin, K. (n.d.). Receptor Binding in Drug Discovery. In eLS.
Jarnagin, K. (2001). Receptor Binding in Drug Discovery. In Encyclopedia of Life Sciences. John Wiley & Sons, Ltd. https://doi.org/10.1038/npg.els.0000056
Jinek, M., & Doudna, J. A. (2009). A three-dimensional view of the molecular machinery of RNA interference. Nature, 457(7228), 405–412. https://doi.org/10.1038/nature07755
Kalluri, R., & Kanasaki, K. (2008). RNA interference: Generic block on angiogenesis. Nature, 452(7187), 543–545. https://doi.org/10.1038/452543a
Kenakin, T. P. (2009). Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nature Reviews Drug Discovery, 8(8), 617–626. https://doi.org/10.1038/nrd2838
Khawaja, X., Dunlop, J., & Kowal, D. (2008). Scintillation proximity assay in lead discovery. Expert Opinion on Drug Discovery, 3(11), 1267–1280. https://doi.org/10.1517/17460441.3.11.1267
Kola, I., & Landis, J. (2004). Opinion: Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3(8), 711–716. https://doi.org/10.1038/nrd1470
Krohn, K. A., & Link, J. M. (2003). Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. Nuclear Medicine and Biology, 30(8), 819–826. https://doi.org/10.1016/S0969-8051(03)00132-X
Leach, Andrew R. & Gillet, Valerie J. (2003). An introduction to chemoinformatics.
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1–3), 3–25. https://doi.org/10.1016/S0169-409X(96)00423-1
Lledo, P.-M., Merkle, F. T., & Alvarez-Buylla, A. (2008). Origin and function of olfactory bulb interneuron diversity. Trends in Neurosciences, 31(8), 392–400. https://doi.org/10.1016/j.tins.2008.05.006
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S. (2011). Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery, 10(3), 188–195. https://doi.org/10.1038/nrd3368
Matter, H. (1997). Selecting Optimally Diverse Compounds from Structure Databases:  A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors. Journal of Medicinal Chemistry, 40(8), 1219–1229. https://doi.org/10.1021/jm960352+
Murray, C. W. (2010). Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. Journal of Medicinal Chemistry, 53(16), 5942–5955. https://doi.org/10.1021/jm100059d
Murray, C. W., & Rees, D. C. (2009). The rise of fragment-based drug discovery. Nature Chemistry, 1(3), 187–192. https://doi.org/10.1038/nchem.217
Nagorsen, D., & Baeuerle, P. A. (2011). Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Experimental Cell Research, 317(9), 1255–1260. https://doi.org/10.1016/j.yexcr.2011.03.010
Nelson, David L., Cox, Michael M., & Lehninger, Albert L. (2008). Lehninger principles of biochemistry (5th ed). W.H. Freeman.
Orengo, Christine Ann, Thornton, Janet M., & Jones, David Tudor. (2003). Bioinformatics: genes, proteins and computers. BIOS. http://www.vlebooks.com/vleweb/product/openreader?id=UCL&isbn=9780203427828
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006). How many drug targets are there? Nature Reviews Drug Discovery, 5(12), 993–996. https://doi.org/10.1038/nrd2199
Patrick, Graham L. (2017). An introduction to medicinal chemistry.
Petsko, Gregory A. & Ringe, Dagmar. (2004). Protein structure and function: Vol. Primers in biology. New Science.
Pillay, V., Gan, H. K., & Scott, A. M. (2011). Antibodies in oncology. New Biotechnology, 28(5), 518–529. https://doi.org/10.1016/j.nbt.2011.03.021
Rang, H. P. & Dale, M. Maureen. (2019). Pharmacology (9th ed). Churchill Livingstone. https://elsevierelibrary.co.uk/product/9780702074462
Richard M. Durbin. (2010). A map of human genome variation from population-scale sequencing. Nature, 467(7319), 1061–1073. https://doi.org/10.1038/nature09534
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006). Antibody targeted drugs as cancer therapeutics. Nature Reviews Drug Discovery, 5(2), 147–159. https://doi.org/10.1038/nrd1957
Selzer, P. M., Rohwer, A., & Marhöfer, R. J. (2008). Applied bioinformatics: an introduction. Springer.
Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., Vargeese, C., Gomez, A., Bouhana, K., Aitchison, R., Pavco, P., & Campochiaro, P. A. (2005). Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Therapy, 13(3), 225–234. https://doi.org/10.1038/sj.gt.3302641
Smith, R. A. (2001). Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorganic & Medicinal Chemistry Letters, 11(20), 2775–2778. https://doi.org/10.1016/S0960-894X(01)00571-6
Stadtfeld, M., & Hochedlinger, K. (2010). Induced pluripotency: history, mechanisms, and applications. Genes & Development, 24(20), 2239–2263. https://doi.org/10.1101/gad.1963910
Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? Nature Reviews Drug Discovery, 10(7), 507–519. https://doi.org/10.1038/nrd3480
Thomas, Gareth. (2003). Fundamentals of medicinal chemistry.
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010). A status report on RNAi therapeutics. Silence, 1(1). https://doi.org/10.1186/1758-907X-1-14
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. https://doi.org/10.1021/jm020017n
Watt, F. M., & Driskell, R. R. (2010). The therapeutic potential of stem cells. Philosophical Transactions of the Royal Society B: Biological Sciences, 365(1537), 155–163. https://doi.org/10.1098/rstb.2009.0149
Webb, S. (2011). Pharma interest surges in antibody drug conjugates. Nature Biotechnology, 29(4), 297–298. https://doi.org/10.1038/nbt0411-297
Weiner, L. M., Surana, R., & Wang, S. (2010). Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology, 10(5), 317–327. https://doi.org/10.1038/nri2744
Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010). Privileged scaffolds for library design and drug discovery. Current Opinion in Chemical Biology, 14(3), 347–361. https://doi.org/10.1016/j.cbpa.2010.02.018
Wilhelm, S. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery, 5(10), 835–844. https://doi.org/10.1038/nrd2130
Willett, P., Barnard, J. M., & Downs, G. M. (1998). Chemical Similarity Searching. Journal of Chemical Information and Modeling, 38(6), 983–996. https://doi.org/10.1021/ci9800211
Woodhead, A. J. (2010). Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. Journal of Medicinal Chemistry, 53(16), 5956–5969. https://doi.org/10.1021/jm100060b
Xiong, Jin. (2006). Essential bioinformatics. Cambridge University Press.
Zvelebil, Marketa J. & Baum, Jeremy O. (2008). Understanding bioinformatics. Garland Science. https://bibliu.com/app/#/view/books/9781136976964/pdf2htmlex/index.html#page_Cover